Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined...
Reexamination Certificate
2001-06-25
2003-02-18
Witz, Jean C. (Department: 1651)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Reexamination Certificate
active
06521263
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to immunomodulatory factors for use in immnunosuppressant and antiallergic treatment.
BACKGROUND OF THE INVENTION
Allergic rhinitis (e.g. hayfever) and asthma are typical results of the immune system response to inhaled molecules such as allergens and antigens. It has been established that the cross-linking of antibodies initiates a series of biochemical and pharmological events including the release of potent mediators of inflammation, which results in allergic reactions, including: difficulty in breathing; itching; excess mucous secretion etc; up to and including life-threatening allergic reactions in some rare situations.
Therapeutically, many agents are used to try to prevent the release of mediators and/or to treat the downstream events by blocking or reducing the effects of the mediators on target tissues. None of the currently available treatments are ideal, and each has problems such as side effects and breakthroughs.
Immunosuppressant compounds induce an inhibition of the immune response system. The immune mediated rejection process is the major cause of graft loss in organ transplantation. Dramatic improvements in immunosuppression and subsequent organ graft and patient survival have been obtained using immunosuppressive compounds.
Autoimmune diseases are disorders where the host discrimination of “self” versus “non-self” breaks down and the individual's immune system (both acquired and innate components) attacks self tissues. Indications are that the main and fundamental error responsible for the induction and persistence of most autoimmune diseases resides within auto-reactive proliferating T lymphocytes.
The currently available immunosuppressant drugs have the disadvantage of a narrow therapeutic range. The compounds are known to be nephrotoxic, neurotoxic and potentially diabetogenic and, therefore are of limited use. Problems also exist with the administration of these compounds, their bioavailability and the monitoring of their levels both clinically and in the laboratory.
The murine trichostrongyle nematode
Heligmesomoides polygyrus
resists the immune system and resides in the mouse duodenum for eight months or more during primary infection. Where immunity is generated against this parasite in artificial experimental situations, it appears to be mediated by Th2 cells and their associated cytokines. However, the parasite has seemingly evolved mechanisms to counteract a potentially protective Th2 response, given the chronicity of natural infections. Simultaneously, infection with
Heligmosomoides polygyrus
suppresses immune responses to a variety of heterologous antigens such as ovine erythrocytes and other nematode parasites normally expelled by what we now know to be Th2 mediated immune mechanisms. Suppressive activity is also demonstrable in vivo, and in vitro using parasite extracts or excretory secretory (ES) products (Pritchard el al, Immunology (1984); 51:633-642 and Pritchard et al, Int. J. Para. (1994); 24:495-500).
SUMMARY OF THE INVENTION
The present invention is based on the isolation of an immunomodulatory factor (IMF) from the nematode
Heligmosomoides polygyrus
which acts to interfere with T cell function, possibly by increasing the production of CD8
+
T cells with a simultaneous decrease in CD4
+
T cells. Therefore, according to the present invention, an immunosuppressive agent is disclosed, wherein the agent is obtainable from the nematode
Heligmosomoides polygyrus
and is characterised by having a molecular weight of less than 12 kDa and being substantially free of bound polypeptides. The agent may be non-proteinaceous.
The agent may be used in the manufacture of a medicament for the treatment of allergic or autoimmune disorders. In particular, the agent may be used in the manufacture of a medicament for the prevention of graft rejection during organ or tissue transplantation. The agent may also be used in the treatment of other autoimmune disorders, for example rheumatoid arthritis and multiple sclerosis.
REFERENCES:
patent: 9629082 (1996-03-01), None
patent: 9933479 (1998-12-01), None
Monroy, Fernando, Colin Dobson and John H. Adams (1989) “Low Molecular Weight Immunosuppressors Secreted by AdultNematospiroides dubius” International Journal of Parasitology19(1):125-128.
Pritchard, D.I., C.E. Lawrence, P. Appleby, I.A. Gibb, and K. Glover (1994) “Immunosuppressive Proteins Secreted By The Gastrointestinal Nematode ParasiteHeligmosomoides polygyrus” Int. J. Parasitol. 24(4):495-500.
Telford, G., d.J. Wheeler, P. Appleby, I.G. bowen, D.I. Pritchard (Dec. 1998) “Heligmosomoides polygyrusimmumomodulatory factor (IMF), targets T-lymphocytes”Parasite Immunology20(12):601-611.
Pritchard David Idris
Williams Paul
Saliwanchik Lloyd & Saliwanchik
University of Nottingham
Witz Jean C.
LandOfFree
Immunomodulatory factors for immunosuppresant and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulatory factors for immunosuppresant and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulatory factors for immunosuppresant and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3178756